Caribou Biosciences, Inc. (CRBU) Total liabilities 2020–2025
Caribou Biosciences, Inc. (CRBU) total liabilities at each fiscal year-end, per SEC filings.
$53.2MFY2025 · since FY2020: $18.2M → $53.2M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $53.2M | -11.9% |
| FY2024 | $60.4M | -5.4% |
| FY2023 | $63.8M | -12.5% |
| FY2022 | $72.9M | +33.7% |
| FY2021 | $54.5M | +200.3% |
| FY2020 | $18.2M | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More CRBU financial trends
CRBU RevenueCRBU Net incomeCRBU Net marginCRBU Gross profitCRBU Gross marginCRBU Operating incomeCRBU Operating marginCRBU Operating cash flowCRBU Free cash flowCRBU Capital expendituresCRBU Return on equityCRBU Stock buybacksCRBU Dividends paidCRBU Total assetsCRBU Shareholders’ equityCRBU overview →